Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.
about
EMT and Treatment Resistance in Pancreatic Cancer.Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer.Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling.Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment.Drug resistance and new therapies in colorectal cancer
P2860
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.
@en
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.
@nl
type
label
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.
@en
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.
@nl
prefLabel
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.
@en
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.
@nl
P2093
P50
P1476
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients
@en
P2093
Camilla Zecchetto
Daniele Rossini
Francesca Ligorio
Francesca Simionato
Gabriella Fontanini
Giampaolo Tortora
Marco Zanotto
Raffaela Santoro
P304
P356
10.1158/1078-0432.CCR-16-3153
P407
P50
P577
2017-03-15T00:00:00Z